Clinical Trial Update: Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the efficacy of Alphanate FVIII/VWF concentrate in patients with Type 3 Von Willebrand Disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Von Willebrand Disease

Drugs mentioned

• Alphanate (antihemophilic factor VIII concentrate)

Snippet

Sponsor: Grifols Biologicals, LLC | Conditions: Von Willebrand Disease | Phase 4 | Status: ACTIVE_NOT_RECRUITING